Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 25,174 shares, a drop of 48.9% from the August 15th total of 49,268 shares. Currently, 2.5% of the shares of the company are short sold. Based on an average daily volume of 188,915 shares, the short-interest ratio is presently 0.1 days.
Clearmind Medicine Price Performance
Shares of NASDAQ:CMND traded down $0.08 during trading on Tuesday, reaching $0.86. 167,080 shares of the company’s stock traded hands, compared to its average volume of 1,013,370. Clearmind Medicine has a fifty-two week low of $0.83 and a fifty-two week high of $524.00. The company has a quick ratio of 4.31, a current ratio of 4.31 and a debt-to-equity ratio of 0.01. The firm has a market cap of $880,721.70, a PE ratio of -0.02 and a beta of 0.81. The company has a 50-day simple moving average of $1.68 and a 200-day simple moving average of $4.78.
Clearmind Medicine (NASDAQ:CMND – Get Free Report) last announced its quarterly earnings results on Thursday, September 10th. The company reported ($0.57) earnings per share for the quarter.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on CMND
About Clearmind Medicine
Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.
Clearmind’s pipeline includes multiple preclinical and early clinical candidates.
Further Reading
- Five stocks we like better than Clearmind Medicine
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
